Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE015 (POL) (Dr. Ito)
· consented 2022-06-19
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
severe
assessed
2026-08-18
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-30 (study day 22); relationship: N
mild
assessed
2026-08-18
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-08-11 (study day 34); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 35); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-08-15 (study day 38); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-14 (study day 68); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.